<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>BRITISH BIOTECH SHARES FALL</title>
    <meta content="MB001644" name="slug"/>
    <meta content="24" name="publication_day_of_month"/>
    <meta content="6" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Saturday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="2" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="3" name="print_column"/>
    <meta content="Health; Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1209829"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="WORLD BUSINESS BRIEFING: EUROPE"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Cancer</classifier>
        <classifier class="indexing_service" type="descriptor">Brain</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Finances</classifier>
        <org class="indexing_service">British Biotech PLC</org>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/World Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Banking, Finance and Insurance</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health</classifier>
        <classifier class="online_producer" type="general_descriptor">Cancer</classifier>
        <classifier class="online_producer" type="general_descriptor">Brain</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Diseases and Conditions</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000624T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=990DE5DD1430F937A15755C0A9669C8B63" item-length="135" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>BRITISH BIOTECH SHARES FALL</hl1>
      </hedline>
      <byline class="print_byline">By Bloomberg News</byline>
      <abstract>
        <p>British Biotech PLC shares lose 20 percent of their value after study shows that its most promising new drug is ineffectual at eradicating certain brain cancers (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>British Biotech P.L.C. lost a fifth of its value after a study showed the company's most advanced experimental medicine provided no benefit in fighting a form of brain cancer. Shares in the company, a biotechnology concern based in Britain, fell 5 pence, to 19.25 pence. British Biotech's shares trade at less than one-tenth of their value four years ago.</p>
      </block>
      <block class="full_text">
        <p>British Biotech P.L.C. lost a fifth of its value after a study showed the company's most advanced experimental medicine provided no benefit in fighting a form of brain cancer. Shares in the company, a biotechnology concern based in Britain, fell 5 pence, to 19.25 pence. British Biotech's shares trade at less than one-tenth of their value four years ago.</p>
        <p>WORLD BUSINESS BRIEFING: EUROPE</p>
      </block>
    </body.content>
  </body>
</nitf>
